← Back to Search

Convulsive Therapy

Convulsive Therapies for Bipolar Disorder (CORRECT-BD Trial)

Waitlist Available
Led By Daniel Blumberger, MD, MSc
Research Sponsored by Centre for Addiction and Mental Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must be voluntary and competent to consent to treatment and research procedures according to ECT/MST attending psychiatrist
Patients must be 18 years of age or older
Must not have
Patients must not have any significant neurological disorder or condition likely to be associated with increased intracranial pressure or a space occupying brain lesion, e.g., cerebral aneurysm
Patients must not have a concomitant major unstable medical illness
Screening 3 weeks
Treatment Varies
Follow Up greater than 8 treatments (2.5 weeks)
Awards & highlights


This trial is testing whether magnetic seizure therapy is more effective and tolerable than electroconvulsive therapy for treating bipolar disorder.

Who is the study for?
This trial is for adults over 18 with non-psychotic Bipolar Disorder (Type I or II) who have a significant level of depression. They must be able to consent, follow the treatment schedule, and keep their current antidepressant constant. Exclusions include major unstable illnesses, pregnancy intention during the study, primary psychotic disorders, recent substance abuse, certain neurological conditions or implants, high doses of benzodiazepines or anticonvulsants.Check my eligibility
What is being tested?
The trial compares Magnetic Seizure Therapy (MST) with Electroconvulsive Therapy (ECT) in treating bipolar depression. It aims to find out if MST can be an effective alternative to ECT by providing better response rates in patients resistant to other treatments.See study design
What are the potential side effects?
While not explicitly listed here, side effects may include memory issues and confusion typically associated with ECT. MST might present similar risks due to its nature as a convulsive therapy but is being studied for potentially fewer cognitive side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am willing and able to agree to treatment and research procedures.
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
I do not have any major brain disorders or conditions that could increase pressure inside my skull.
I do not have any major unstable illnesses.
I don't take more than 2 mg/day of lorazepam or any similar medication.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~greater than 8 treatments (2.5 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and greater than 8 treatments (2.5 weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cognitive adverse effects as indexed by the Autobiographical Memory Test (AMT)
Remission (score </= 10) on the Hamilton Rating Scale for Depression - 24 (HRSD-24)
Secondary outcome measures
Improvement in symptom severity of Suicidal Ideation as measured by the Scale for Suicidal Ideation (SSI)
Number of self-reported and clinical-reported adverse events

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Magnetic Seizure Therapy (MST)Experimental Treatment1 Intervention
MST treatments will be administered using the MagPro MST with Cool TwinCoil.
Group II: Electroconvulsive Therapy (ECT)Active Control1 Intervention
ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma

Find a Location

Who is running the clinical trial?

Centre for Addiction and Mental HealthLead Sponsor
359 Previous Clinical Trials
81,459 Total Patients Enrolled
University of British ColumbiaOTHER
1,431 Previous Clinical Trials
2,478,803 Total Patients Enrolled
Brain CanadaOTHER
18 Previous Clinical Trials
5,900 Total Patients Enrolled

Media Library

ECT (Convulsive Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03641300 — N/A
Depression, Bipolar Disorder Research Study Groups: Electroconvulsive Therapy (ECT), Magnetic Seizure Therapy (MST)
Depression, Bipolar Disorder Clinical Trial 2023: ECT Highlights & Side Effects. Trial Name: NCT03641300 — N/A
ECT (Convulsive Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03641300 — N/A
~15 spots leftby Jul 2025